DRUG · Mapped RxNorm record
Abemaciclib
Normalized identity: abemaciclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT02441946
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Loperamide
Normalized identity: loperamideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Anastrozole
Normalized identity: anastrozoleView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Hormone Receptor Positive Tumorunresolved
Early-Stage Breast Carcinomaunresolved
Interventions
AbemaciclibDRUG · verified · RxNorm: abemaciclib
LoperamideDRUG · verified · RxNorm: loperamide
AnastrozoleDRUG · verified · RxNorm: anastrozole
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
Los AngelesCalifornia, United States2New YorkNew York, United States1HoustonTexas, United States1MiamiFlorida, United States1MadridSpain1BerlinGermany1OrlandoFlorida, United States1DenverColorado, United States1MilanItaly1TaipeiTaiwan1Salt Lake CityUtah, United States1BethesdaMaryland, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02441946 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.